Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY, 10029, USA.
Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Abdom Radiol (NY). 2017 Jan;42(1):179-190. doi: 10.1007/s00261-016-0841-5.
The purpose of this study was to evaluate the diagnostic performance of a "simulated" abbreviated MRI (AMRI) protocol using diffusion-weighted imaging (DWI) and T1-weighted (T1w) imaging obtained at the hepatobiliary phase (HBP) post gadoxetic acid injection alone and in combination, compared to dynamic contrast-enhanced (CE)-T1w imaging for the detection of hepatocellular carcinoma (HCC).
This was an IRB approved HIPAA compliant retrospective single institution study including patients with liver disease who underwent gadoxetic acid-enhanced MRI for HCC diagnosis. Three independent observers assessed 2 sets of images (full CE-set and AMRI including DWI+T1w-HBP). Diagnostic performance of T1w-HBP and DWI alone and in combination was compared to that of CE-set. All imaging sets included unenhanced T1w and T2w sequences. A preliminary analysis was performed to assess cost savings of AMRI protocol compared to a full MRI study.
174 patients including 62 with 80 HCCs were assessed. Equivalent per-patient sensitivity and negative predictive value (NPV) were observed for DWI (85.5% and 92.2%, pooled data) and T1w-HBP (89.8% and 94.2%) (P = 0.1-0.7), while these were significantly lower for the full AMRI protocol (DWI+T1w-HBP, 80.6% and 80%, P = 0.02) when compared to CE-set (90.3% and 94.9%). Higher specificity and positive predictive value were observed for CE-set vs. AMRI (P = 0.02). The estimated cost reduction of AMRI versus full MRI ranged between 30.7 and 49.0%.
AMRI using DWI and T1w-HBP has a clinically acceptable sensitivity and NPV for HCC detection. This could serve as the basis for a future study assessing AMRI for HCC screening and surveillance.
本研究旨在评估单独及联合使用钆塞酸后肝胆期(HBP)T1 加权成像(T1w)和弥散加权成像(DWI)获得的“模拟”缩短磁共振成像(AMRI)方案与动态对比增强(CE)-T1w 成像在检测肝细胞癌(HCC)方面的诊断性能。
这是一项经机构审查委员会批准并符合 HIPAA 规定的回顾性单中心研究,纳入了因 HCC 诊断而行钆塞酸增强 MRI 的肝病患者。3 名独立观察者评估了 2 组图像(完整 CE 组和包含 DWI+HBP-T1w 的 AMRI 组)。单独和联合使用 T1w-HBP 和 DWI 的诊断性能与 CE 组进行比较。所有成像组均包括未增强的 T1w 和 T2w 序列。进行了初步分析以评估 AMRI 方案与完整 MRI 研究相比的成本节约。
共评估了 174 名患者,其中 62 名患者有 80 个 HCC。DWI(85.5%和 92.2%,汇总数据)和 T1w-HBP(89.8%和 94.2%)的个体患者敏感性和阴性预测值(NPV)相当(P=0.1-0.7),而当与 CE 组相比时,全 AMRI 方案(DWI+T1w-HBP)的这些值显著更低(80.6%和 80%,P=0.02)。CE 组与 AMRI 组相比,特异性和阳性预测值更高(P=0.02)。AMRI 与全 MRI 相比,估计成本降低幅度在 30.7%至 49.0%之间。
使用 DWI 和 T1w-HBP 的 AMRI 方案在 HCC 检测方面具有可接受的敏感性和 NPV。这可以作为未来评估 AMRI 用于 HCC 筛查和监测的研究基础。